CTRI/2026/02/103794 [Registered on: 13/02/2026] Trial Registered Prospectively
Last Modified On:
13/02/2026
Post Graduate Thesis
Yes
Type of Trial
Interventional
Type of Study
Ayurveda
Study Design
Single Arm Study
Public Title of Study
To check how Ayurvedic Treatment works for Chronic Kidney Disease.
Scientific Title of Study
A Single Arm Clinical Study to evaluate the effect of Ayurvedic Treatment Protocol of Chronic Kidney Disease
Trial Acronym
NIL
Secondary IDs if Any
Secondary ID
Identifier
NIL
NIL
Details of Principal Investigator or overall Trial Coordinator (multi-center study)
Name
Dr Riddhi Anil Jain
Designation
PG Scholar
Affiliation
Seth Govindji Raoji Ayurveda Mahavidylaya Solapur
Address
Opd no 2,3,10 Kayachikista Department Seth Sakharam Nemchand Jain Ayurveda Rugnalaya 118/119 shukrawar peth near juni faujdar chawdi Solapur MAHARASHTRA 413002 India
Solapur MAHARASHTRA 413002 India
Phone
9021995436
Fax
Email
riddhi.jain@pg.sgrayurved.edu.in
Details of Contact Person Scientific Query
Name
Dr Santosh I Swami
Designation
Associate Professor Kayachikitsa Department
Affiliation
Seth Govindji Raoji Ayurveda Mahavidylaya Solapur
Address
Seth Sakharam Nemchand Jain Ayurveda Rugnalaya,118/119 shukrawar peth near juni faujdar chawdi Solapur MAHARASHTRA 413002 India
Solapur MAHARASHTRA 413002 India
Phone
9422957234
Fax
Email
santosh.swami@sgrayurved.edu.in
Details of Contact Person Public Query
Name
Dr Riddhi Anil Jain
Designation
PG Scholar
Affiliation
Seth Govindji Raoji Ayurveda Mahavidylaya Solapur
Address
Seth Sakharam Nemchand Jain Ayurveda Rugnalaya,118/119 shukrawar peth near juni faujdar chawdi Solapur MAHARASHTRA 413002 India
Solapur
MAHARASHTRA
413002
India
Solapur MAHARASHTRA 413002 India
Phone
9021995436
Fax
Email
riddhi.jain@pg.sgrayurved.edu.in
Source of Monetary or Material Support
Seth Sakharam Nemchand Jain Ayurveda Rugnalaya 118/119 shukrawar peth near juni faujdar chawdi Solapur MAHARASHTRA 413002 India
Primary Sponsor
Name
Dr Riddhi Anil Jain
Address
Seth Sakharam Nemchand Jain Ayurveda Rugnalaya 118/119 shukrawar peth near juni faujdar chawdi Solapur MAHARASHTRA 413002 India
Type of Sponsor
Other [Self]
Details of Secondary Sponsor
Name
Address
Nil
Nil
Countries of Recruitment
India
Sites of Study
No of Sites = 1
Name of Principal
Investigator
Name of Site
Site Address
Phone/Fax/Email
Dr Riddhi Anil Jain
Seth Sakharam Nemchand Jain Ayurveda Rugnalya
Kayachikista OPD 2 3 Seth Sakharam Nemchand Jain Ayurveda Rugnalaya, 118/119 shukrawar peth, near juni faujdar chawdi Solapur MAHARASHTRA 413002 India
Solapur
MAHARASHTRA
Solapur MAHARASHTRA
(Procedure Reference: Sushruta Samhita, Procedure details: Snehana and Swedana will be done before basti .
The procedure will be done on an empty stomach.
Patient will be asked to lie down in the left lateral position with the left leg straight and full flexion of the right leg from the knee and hip joint.
Mutravirechaniyagana Gana Niruha Basti will be administered and the patient will be asked to take a deep breath lie down in the supine position.
After the procedure, the patient will be asked to take rest until the motion comes and advised to go for motion whenever he feels the urge.
Basti will be given on 2nd,3rd,4th,6th,7th,8th,10th,11th,12th,14th day of the intervention
) (1) Medicine Name: Mutravirechaniya Gana, Reference: Charaka Samhita: Sutra Sthana 4/35, Route: Rectal, Dosage Form: Kwatha/Kashaya, Dose: 420(ml), Frequency: od, Duration: 10 Days
4
Intervention Arm
Procedure
-
anuvAsana-bastiH, अनुवासन-बस्तिः
(Procedure Reference: Susharut Samhita, Procedure details: Snehana and Swedana will be done before procedure.
The procedure will be done immediately after meal.
The patient will be made to lie down in the left lateral position with the left leg straight and the right leg fully flexed at knee and hip.
Mutravirechaniyagana Gana siddha tail will be administered by applying steady pressure and ask to take a deep breath through the mouth during the procedure. The patient will be made to lie down in the supine position.
The patient will be advised to go for defecation whenever the urge is feel Post-procedure evaluation will be recorded.
Anuvasana basti will be given on 1st,5th,9th,13th,15th,16th day of day intervention
) (1) Medicine Name: Mutravirechaniyagana Gana , Reference: Charaka Samhita: Sutra Sthana 4/35, Route: Rectal, Dosage Form: Taila, Dose: 60(ml), Frequency: od, Duration: 6 Days
Inclusion Criteria
Age From
20.00 Year(s)
Age To
70.00 Year(s)
Gender
Both
Details
Subject having signs and symptoms of chronic kidney disease with serum creatinine level between1.4-3 mg/dl, eGFR level above 40 ml/min, Blood urea level below 50 mg/dl
Subject full filling any two or more of these criteria
ExclusionCriteria
Details
Female subject having pregnancy, breast feeding or post-delivery period.
Subject of end stage renal failure, who are on dialysis treatment, who are already operated for renal transplantation and then having
nephropathy, hepato-renal insufficiency or renal insufficiency due to
hemodynamic circulatory disorders and CCF.
Subject having some serious illness like cardio-vascular diseases, acute mental
disorders, serious acute organic diseasesm, having Haemoglobin concentration below 6gm and sunject unfit for basti.
Method of Generating Random Sequence
Not Applicable
Method of Concealment
Not Applicable
Blinding/Masking
Open Label
Primary Outcome
Outcome
TimePoints
To assess improvement in CKD-related clinical symptoms (e.g. pedal edema, tiredness, breathlessness, nausea, insomnia, anorexia) using validated symptom scales and serum creatinine, blood urea and eGFR level.
46 days
Secondary Outcome
Outcome
TimePoints
To study the pathogenesis of CKD according to Ayurved and modern perspective.
46 days
Target Sample Size
Total Sample Size="15" Sample Size from India="15" Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials" Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials"
Phase of Trial
N/A
Date of First Enrollment (India)
24/02/2026
Date of Study Completion (India)
Applicable only for Completed/Terminated trials
Date of First Enrollment (Global)
Date Missing
Date of Study Completion (Global)
Applicable only for Completed/Terminated trials
Estimated Duration of Trial
Years="1" Months="5" Days="28"
Recruitment Status of Trial (Global)
Not Applicable
Recruitment Status of Trial (India)
Not Yet Recruiting
Publication Details
N/A
Individual Participant Data (IPD) Sharing Statement
Will individual participant data (IPD) be shared publicly (including data dictionaries)?
Response - NO
Brief Summary
Chronic kidney disease (CKD) represents a progressive spectrum of pathophysiological processes characterized by abnormal renal function and a gradual decline in glomerular filtration rate (GFR). Chronic renal failure, typically corresponding to CKD stages 3–5, reflects significant irreversible nephron loss, while end-stage renal disease (ESRD) denotes the critical stage where toxin, fluid, and electrolyte accumulation leads to uremic syndrome, necessitating renal replacement therapy such as dialysis or transplantation.
Identification of risk factors—including hypertension, diabetes mellitus, autoimmune disorders, advanced age, family history of renal disease, prior acute kidney injury, proteinuria, abnormal urinary sediment, and structural urinary tract abnormalities .
The major etiologies of CKD comprise diabetes mellitus (20–40%), interstitial kidney diseases (20–30%), glomerular diseases (10–20%), hypertension (5–20%), and systemic inflammatory diseases (5-10%),renal artery stenosis and congenital/inherited disorders such as polycystic kidney disease and Alport’s syndrome account for a minority (~5%) of cases, the rising prevalence in India reflects broader epidemiologic transition.
Diagnosis primarily relies on serum creatinine measurement, an indicator of reduced glomerular filtration rate (GFR) and impaired waste excretion.
Ayurvedic perspective
In Ayurveda, CKD does not correspond directly to any single named condition. According to Charaka Samhita Sutrasthana, not all diseases are named instead, Treatment is based on understanding the disease nature, site, and cause. CKD can be considered a disorder of the MutravahaSrotas (urinary channels), involving aggravation of Vata and Kapha doshas along with vitiation of multiple Dushyas (tissues), initially affecting Rasa, Rakta, Mutra, and Udaka, and later all Dhatus.
Mutravirechaniya Gana with Anuvasan and Niruha Basti in Ayurveda supports chronic kidney disease by promoting diuresis, reducing fluid retention, balancing Vata-Kapha, detoxifying metabolic wastes, nourishing renal tissues, and easing urinary inflammation, thereby aiding kidney function holistically alongside medical supervision.
Trinpanchamool Kashayam traditionally aids chronic kidney conditions by enhancing urine flow, reducing inflammation, flushing toxins, balancing Vata-Kapha doshas, and nourishing urinary tissues. Ayurveda views it as supportive, though modern nephrology emphasizes medical treatment; professional guidance remains essential for safe integration.
Vastyaamantaka Ghritapana, an Ayurvedic medicated ghee, is believed to reduce inflammation, balance doshas, improve renal circulation, support detoxification, and enhance tissue repair, potentially aiding chronic kidney disease management holistically.